viewSUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals grants Mitsubishi Tanabe Korea an exclusive licence for ZolpiMist

SUDA to receive an upfront fee of US$100,000 plus a regulatory milestone of a further US$100,000 on approval.

SUDA Pharmaceuticals Ltd - SUDA Pharmaceuticals grants Mitsubishi Tanabe Korea an exclusive licence for ZolpiMist
The company will also receive a 12% royalty

SUDA Pharmaceuticals Ltd (ASX:SUD) has entered into an exclusive license agreement with the South Korean subsidiary of Mitsubishi Tanabe Pharma Corporation (OTCMKTS:MTZPY).

The agreement is for an exclusive licence for, and supply of, ZolpiMist for South Korea with a term of ten years from first commercial sale. ZolpiMist is a first-in-class oral spray of zolpidem for insomnia.

SUDA will receive an upfront fee of US$100,000 and a milestone payment based on Mitsubishi obtaining regulatory approval of US$100,000 as well as commercial milestone payments based on Mitsubishi achieving sales targets of the product up to a maximum series of milestone payments of US$300,000.

Potential coverage across Asia

SUDA executive director of business development David Phillips said: “We are very excited with the prospect of this partnership which will expand ZolpiMist coverage across Asia with MTPC.

“By completing another agreement with the MTPC, we continue to make progress with the build out of the commercialization of ZolpiMist into Korea and are in discussions with multiple parties for other territories also.”

12% royalty

As per the terms of the new agreement, SUDA will receive a double-digit royalty (12%) based on net sales of the product in South Korea.

SUDA’s obligations include the registration of ZolpiMist with the Australian TGA and the supply of ZolpiMist for which SUDA will receive a handling fee.

SUDA and Mitsubishi will work together to coordinate and oversee activities to ensure the success of the product in South Korea.

Quick facts: SUDA Pharmaceuticals Ltd

Price: 0.04 AUD

Market: ASX
Market Cap: $12.27 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of SUDA Pharmaceuticals Ltd named herein, including the promotion by the Company of SUDA Pharmaceuticals Ltd in any Content on the Site, the...


Suda Pharmaceuticals' Dr Michael Baker hails regulatory approval for lead...

Dr Michael Baker, CEO of SUDA Pharmaceuticals Ltd (ASX:SUD), speaks to Proactive's Andrew Scott soon after announcing they've received Therapeutics Goods Administration (TGA) approval for their lead product ZolpiMist for the treatment of short-term insomnia in adults. Baker says it's a...

on 31/7/20

2 min read